Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

165 - The clinical efficacy of apatinib combined with Xeloda in advanced triple negative breast cancer


24 Nov 2018


Poster display - Cocktail


Tumour Site

Breast Cancer


YiHui Li


Annals of Oncology (2018) 29 (suppl_9): ix13-ix20. 10.1093/annonc/mdy428


Y. Li, Y. Wang

Author affiliations

  • Oncology Comprehensive Treatment Division, Tangshan People's Hospital, 063000 - Tangshan/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 165


This study aimed to evaluate the clinical efficacy of apatinib combined with capecitabine in advanced triple-negative breast cancer patients who failed second-line treatment.


From October 2015 to April 2017, we retrospectively screened 53 patients who had been diagnosed with advanced triple-negative breast cancer in our hospital. Experimental group: 26 patients with apatinib (250 mg, qd, orally) and capecitabine (1250mg/m2, bid, d1-14, orally), treatment was continued until disease progression. Control group :27 patients with capecitabine (1250mg/m2, bid, d1-14, orally). The objective response rate, disease control rate and adverse events of the two groups were compared.


The objective response rate and disease control rate in the experimental group was significantly higher than in the control group. The objective response rateswere 30.8% and 3.7%, respectively. The disease control rates were 65.4% and 29.6%, respectively. There were no significant differences in the adverse events between the two groups except grade I-II hypertension and I-II bleeding.


Apatinib combined with capecitabine is efficacious in treating patients with triple-negative breast cancer who failed second-line treatment, with acceptable toxic effects.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Yihui Li.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.